Total Payments
$431,759
2024 Payments
$18,763
Companies
40
Transactions
1,015
Medicare Patients
753
Medicare Billing
$426,341
Payment Breakdown by Category
Other$296,078 (68.6%)
Consulting$85,004 (19.7%)
Travel$25,263 (5.9%)
Food & Beverage$22,086 (5.1%)
Research$2,908 (0.7%)
Education$420.42 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $259,370 | 154 | 60.1% |
| Consulting Fee | $85,004 | 51 | 19.7% |
| Honoraria | $36,620 | 18 | 8.5% |
| Travel and Lodging | $25,263 | 82 | 5.9% |
| Food and Beverage | $22,086 | 698 | 5.1% |
| Unspecified | $2,908 | 2 | 0.7% |
| Education | $420.42 | 8 | 0.1% |
| Grant | $87.90 | 2 | 0.0% |
Payments by Type
General
$428,851
1,013 transactions
Research
$2,908
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $132,925 | 164 | $0 (2023) |
| Lilly USA, LLC | $59,977 | 107 | $0 (2024) |
| IMPEL PHARMACEUTICALS INC. | $59,466 | 37 | $0 (2023) |
| Lundbeck LLC | $37,681 | 86 | $0 (2024) |
| ABBVIE INC. | $35,402 | 180 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $17,771 | 72 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $17,709 | 26 | $0 (2021) |
| Allergan, Inc. | $15,110 | 68 | $0 (2022) |
| BioDelivery Sciences International, Inc. | $11,779 | 13 | $0 (2022) |
| Avanir Pharmaceuticals, Inc. | $10,336 | 24 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,763 | 97 | ABBVIE INC. ($8,747) |
| 2023 | $46,151 | 134 | IMPEL PHARMACEUTICALS INC. ($28,493) |
| 2022 | $82,431 | 161 | IMPEL PHARMACEUTICALS INC. ($30,973) |
| 2021 | $77,994 | 210 | Amgen Inc. ($26,250) |
| 2020 | $54,006 | 159 | Lundbeck LLC ($15,082) |
| 2019 | $72,938 | 140 | Amgen Inc. ($39,979) |
| 2018 | $63,135 | 86 | Amgen Inc. ($40,541) |
| 2017 | $16,340 | 28 | Amgen Inc. ($13,077) |
All Payment Transactions
1,015 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $28.28 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $6.77 | General |
| Category: Analgesic | ||||||
| 12/10/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $2.72 | General |
| Category: Analgesic | ||||||
| 12/10/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $1.66 | General |
| Category: Analgesic | ||||||
| 12/04/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $4.42 | General |
| Category: NEUROLOGY | ||||||
| 11/26/2024 | SCILEX PHARMACEUTICALS INC. | ELYXYB - CELECOXIB (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Pain Management | ||||||
| 11/20/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $26.63 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/20/2024 | Lilly USA, LLC | EMGALITY (Drug), REYVOW | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: Neuroscience | ||||||
| 11/19/2024 | ABBVIE INC. | UBRELVY (Drug) | Travel and Lodging | In-kind items and services | $65.55 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | SCILEX PHARMACEUTICALS INC. | ELYXYB - CELECOXIB (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Pain Management | ||||||
| 11/12/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 11/12/2024 | SCILEX PHARMACEUTICALS INC. | ELYXYB - CELECOXIB (Drug) | Food and Beverage | In-kind items and services | $158.76 | General |
| Category: Pain Management | ||||||
| 11/12/2024 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $18.81 | General |
| Category: Central Nervous System | ||||||
| 11/08/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $36.38 | General |
| Category: Neuropsychiatry | ||||||
| 11/07/2024 | SCILEX PHARMACEUTICALS INC. | ELYXYB - CELECOXIB (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Pain Management | ||||||
| 10/31/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $28.09 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | SCILEX PHARMACEUTICALS INC. | ELYXYB - CELECOXIB (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Pain Management | ||||||
| 10/28/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $25.81 | General |
| Category: Neuroscience | ||||||
| 10/28/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: Neuropsychiatry | ||||||
| 10/23/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $110.56 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Travel and Lodging | In-kind items and services | $4.35 | General |
| Category: NEUROSCIENCE | ||||||
| 10/22/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $23.96 | General |
| Category: NEUROLOGY | ||||||
| 10/08/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | Eli Lilly and Company | $2,850 | 1 |
| RANDOMIZED CONTROLLED TRIAL OF LASMIDITAN OVER FOUR MIGRAINE ATTACKS | Eli Lilly and Company | $57.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 175 | 16,132 | $504,969 | $112,227 |
| 2022 | 7 | 182 | 15,060 | $424,478 | $104,446 |
| 2021 | 7 | 206 | 14,954 | $411,311 | $107,713 |
| 2020 | 7 | 190 | 15,948 | $378,658 | $101,954 |
Total Patients
753
Total Services
62,094
Medicare Billing
$426,341
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 25 | 15,810 | $386,080 | $77,078 | 20.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 45 | 85 | $33,417 | $11,788 | 35.3% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 25 | 87 | $47,208 | $10,392 | 22.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 56 | $15,666 | $5,443 | 34.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 24 | 24 | $11,876 | $4,197 | 35.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 35 | $6,520 | $2,398 | 36.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 12 | 35 | $4,202 | $930.97 | 22.2% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 24 | 14,710 | $311,085 | $69,718 | 22.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 49 | 90 | $35,167 | $12,464 | 35.4% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 24 | 76 | $40,520 | $9,357 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 22 | 53 | $15,392 | $5,029 | 32.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 20 | 20 | $9,269 | $3,578 | 38.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 30 | 83 | $7,885 | $2,289 | 29.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 28 | $5,160 | $2,011 | 39.0% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 22 | 14,544 | $295,115 | $67,857 | 23.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 42 | 88 | $32,458 | $13,097 | 40.3% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2021 | 22 | 73 | $36,470 | $9,135 | 25.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 44 | 77 | $20,972 | $7,796 | 37.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 23 | 23 | $10,350 | $3,946 | 38.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 33 | 111 | $8,425 | $3,110 | 36.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 20 | 38 | $7,521 | $2,773 | 36.9% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 26 | 15,665 | $278,970 | $73,954 | 26.5% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2020 | 26 | 71 | $30,310 | $8,882 | 29.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 31 | 47 | $19,321 | $4,982 | 25.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 37 | 58 | $18,616 | $4,982 | 26.8% |
About Dr. Hossein Ansari, M.D
Dr. Hossein Ansari, M.D is a Neurology healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/25/2007. The National Provider Identifier (NPI) number assigned to this provider is 1578774949.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hossein Ansari, M.D has received a total of $431,759 in payments from pharmaceutical and medical device companies, with $18,763 received in 2024. These payments were reported across 1,015 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($259,370).
As a Medicare-enrolled provider, Ansari has provided services to 753 Medicare beneficiaries, totaling 62,094 services with total Medicare billing of $426,341. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location San Diego, CA
- Active Since 05/25/2007
- Last Updated 10/22/2018
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1578774949
Products in Payments
- Aimovig (Biological) $104,253
- Trudhesa (Drug) $59,466
- EMGALITY (Drug) $45,149
- VYEPTI (Biological) $37,670
- UBRELVY (Drug) $37,161
- NURTEC ODT (Drug) $26,307
- ELYXYB - CELECOXIB (Drug) $16,188
- QULIPTA (Drug) $10,734
- AJOVY (Drug) $10,344
- ONZETRA Xsail (Drug) $9,774
- AIMOVIG (Biological) $5,082
- TROKENDI XR (Drug) $4,693
- ELYXYB - celecoxib (Drug) $3,900
- AJOVY (Biological) $3,124
- INGREZZA (Drug) $885.45
- BOTOX (Biological) $687.00
- VRAYLAR (Drug) $579.65
- ZEMBRACE SYMTOUCH (Drug) $518.12
- NUEDEXTA (Drug) $477.57
- SPRAVATO (Drug) $352.51
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in San Diego
Dr. Revere Kinkel, M.d, M.D
Neurology — Payments: $432,113
Neurology $432,113
Nathaniel Schuster, M.d, M.D
Neurology — Payments: $313,162
Neurology $313,162
Dr. Monali Patel, M.d, M.D
Neurology — Payments: $251,383
Neurology $251,383
Jennifer Graves, Md, MD
Neurology — Payments: $138,828
Neurology $138,828
Dr. Jose Soria-Lopez, Md, MD
Neurology — Payments: $108,135
Neurology $108,135
Dr. Royya Modir, M.d, M.D
Neurology — Payments: $101,774
Neurology $101,774